echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Two new indications for BeiGene PD-1 monoclonal antibody will be approved soon

    Two new indications for BeiGene PD-1 monoclonal antibody will be approved soon

    • Last Update: 2021-08-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, the official website of the State Food and Drug Administration showed that BeiGene's PD-1 antibody drug Bezeran (Tilelizumab) has been in the "approval" stage for two new indications (acceptance number: CXSS2000032, CXSS2000033).


    The two indications to be approved this time are: 1) Combined chemotherapy for the treatment of patients with first-line advanced non-squamous non-small cell lung cancer (NSCLC)


    An open, multi-center, randomized phase III clinical trial code-named RATIONALE 304 evaluated the combination of pemetrexed with pemetrexed and platinum-based chemotherapy drugs (carboplatin or cisplatin), compared with pemetrexed and platinum only Class chemotherapeutics, curative effect in the treatment of first-line stage IIIB or IV non-squamous NSCLC patients


    As of the data cut-off point of January 23, 2020, the median follow-up time was 9.


    A pivotal phase II clinical trial (NCT03419897) evaluated the efficacy of Bezan in the treatment of unresectable HCC patients who had previously received treatment


    Attached table: PD1/PD-L1 domestic application for listing and approval

    Attached table: PD1/PD-L1 domestic application for listing and approval

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.